Overview

CJC-1295 (Without DAC) and Ipamorelin are two peptides that are often researched together as a complementary stack within the field of growth hormone and metabolic science.

Each peptide works through a different pathway, which is why researchers frequently investigate them in combination. While CJC-1295 (Without DAC) is explored for its interaction with growth hormone-releasing hormone (GHRH) pathways, Ipamorelin is studied for its activity involving ghrelin receptor signalling.

Because of their distinct but related mechanisms, this stack has become one of the most recognised peptide combinations within endocrine research.

Mechanism of Interest

Researchers are interested in this combination because it targets two separate signalling pathways involved in growth hormone regulation.

CJC-1295 (Without DAC)

CJC-1295 (Without DAC) is a synthetic peptide designed to mimic the action of growth hormone-releasing hormone (GHRH), which naturally occurs in the body.

Researchers continue to investigate how it influences:

• Growth hormone-related signalling pathways

• Endocrine communication

• Metabolic regulation

Ipamorelin

Ipamorelin is a selective peptide that interacts with ghrelin receptors, which are involved in growth hormone release mechanisms.

Current areas of investigation include:

• Growth hormone dynamics

• Ghrelin receptor activity

• Peptide signalling pathways

Areas of Ongoing Research

The CJC-1295 (Without DAC) and Ipamorelin combination is currently being investigated within several areas of scientific research, including:

• Growth hormone signalling

• Endocrine function

• Metabolic health research

• Exercise physiology studies

• Healthy ageing investigations

Researchers continue to explore how these peptides may complement one another within broader models of endocrine biology.

Why Researchers Are Interested in CJC-1295 + Ipamorelin

This combination has become particularly popular because it brings together two different approaches to investigating growth hormone-related pathways.

For beginners, one of the easiest ways to think about it is this:

CJC-1295 (Without DAC) is often researched for its involvement in signalling the body to release growth hormone, while Ipamorelin is explored for its interaction with receptors associated with that same process.

Because these peptides work through different mechanisms of interest, researchers frequently investigate them together when studying growth hormone dynamics and endocrine function.

As a result, CJC-1295 (Without DAC) and Ipamorelin have become one of the most widely recognised peptide stacks within this area of research.

Related Compounds

Researchers exploring CJC-1295 (Without DAC) and Ipamorelin may also be interested in:

• Tesamorelin

• CJC-1295 (With DAC)

• MK-677

• MOTS-C

• NAD+

While these compounds differ in their mechanisms of interest, they share overlapping areas of scientific investigation involving metabolism, endocrine signalling, and healthy ageing research.

Disclaimer

The information provided above is intended for educational and research purposes only.

CJC-1295 (Without DAC) and Ipamorelin supplied by Sterling Prime Peptides are strictly intended for laboratory and in vitro research use only.

These products are not intended for human consumption, clinical use, diagnosis, treatment, or prevention of disease. Researchers should conduct their own due diligence and consult the available scientific literature before commencing any investigational work.

Interested in future product launches?

Join the Sterling Prime newsletter to be the first to know when new research compounds become available.

Precision. Purity. Consistency.